This group supports the Environmental Protection Agency’s (EPA) efforts to protect public health and the environment through the Residual Risk and Technology Review (RTR) process and recognizes the
need to develop stringent emissions standards to mitigate any potential hazards posed by Ethylene Oxide (EtO) emissions. However, they are also cautious of the impact these changes may have on the availability and timely delivery of biotherapeutics to patients who rely on them. Biotherapeutics, including vaccines, therapeutics, and other life-saving medications, play a crucial role in improving patient health outcomes and saving lives. For the biopharmaceutical industry, EtO sterilization is a critical process used to ensure product safety and efficacy. The EtO Response team raised several concerns regarding the potential impact of the proposed rule changes on the biotherapeutics market. This document discusses the concerns.
Development Group
Viewing related articles
Viral clearance paper implementation tracking survey results 2022
Apr 2023 | Benchmarking, Deliverable, Deliverables Report, Development Group, POI - Development Group, Viral Clearance
For the last three years, the BioPhorum Viral Clearance team have completed a short survey on their published papers to understand how they have been used and the response of regulators if used to support filings. This is the report for 2022
Survey to evaluate the current use of PAT software for chemometrics and PAT infrastructure
Apr 2023 | Benchmarking, Deliverable, Deliverables Report, Development Group, PAT Monitoring and Control, POI - Development Group
A BioPhorum member only survey that aims to tackle questions around the types of PAT software for chemometrics and PAT infrastructure used, ease of instalment, its advantages and limitations
BioPhorum feedback on ICH Q5A (R2)
Mar 2023 | Cell & Gene Therapy, Deliverable, Deliverables Report, Development Group, Drug Substance, Feedback to agency, POI - Development Group, Regulatory, Regulatory Governance, Supply Partner
BioPhorum’s in-depth feedback includes 70 line-by-line, detailed comments, including the rationale for the points and any proposed changes/recommendations that are deemed necessary by the team to ensure a harmonized implementation across industry and regulatory agencies.
BioPhorum environmental sustainability roadmap 2022
Dec 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, Development Group, Drug Substance, Fill Finish, Information Technology, MediPhorum, POI - Sustainability, Publication, Regulatory, Supply Chain to Patient, Supply Partner, Sustainability, Technology Strategy
Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health. The healthcare sector is responsible for 4–5% of global emissions, more than 70% of which are driven by supply chains.
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
Nov 2022 | Deliverable, Deliverables Report, Development Group, Formulation and Drug Product Development, Publication
To understand industry approaches for developing high-concentration formulations, BioPhorum Development Group Formulation workstream conducted an inter-company collaborative exercise which included several surveys. This collaboration provided an industry perspective, experience, and insight into the practicalities for developing high-concentration biologics.
Characterization and risk assessment of host cell proteins using mass spectrometry
Nov 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A BioPhorum member survey to gather preliminary information from across the biopharmaceutical industry on the characterization and risk assessment of HCP using mass spectrometry.
Enzymatic activity assays – general usage assessment
Nov 2022 | Benchmarking, Deliverable, Deliverables Report, Development Group, Host Cell Proteins and other Bioresidual Impurities
A BioPhorum member only survey to share knowledge into how, why and when enzymatic activity assays are performed.
Industry approaches for implementation of ready to use ( RtU ) cells in bioassays
Oct 2022 | Bioassay, Conference, Deliverable, Deliverables Report, Development Group, POI - Development Group
This poster recently presented at CASSS Bioassay and BEPA describes selected results of an industry collaboration to encourage discussion on common approaches to ready to use (RtU) for bioassays cell manufacturing, testing and implementation across the industry.
Viral Clearance worst-case conditions presentation at PDA Viral Clearance conference
Jun 2022 | Conference, Deliverable, Deliverables Report, Development Group, Viral Clearance
This member only resource developed by the BioPhorum Development Group Viral Clearance team is based on their analysis of the worst-case conditions benchmarking survey and was presented at the PDA Viral Clearance conference in Brussels in June 2022.Â